Primary reconstruction with implants in breast cancer

Aspects of oncological safety and aesthetic outcome

Catharina Eriksen
“Du ska få en dag i månå som rein og ubrukt står”

(Alf Prøysen)
## CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABSTRACT</td>
<td>1</td>
</tr>
<tr>
<td>LIST OF ABBREVIATIONS</td>
<td>2</td>
</tr>
<tr>
<td>LIST OF PUBLICATIONS</td>
<td>3</td>
</tr>
<tr>
<td>INTRODUCTION</td>
<td>5</td>
</tr>
<tr>
<td>BACKGROUND</td>
<td>7</td>
</tr>
<tr>
<td><strong>BREAST CANCER</strong></td>
<td>7</td>
</tr>
<tr>
<td>Epidemiology</td>
<td>7</td>
</tr>
<tr>
<td>Etiology</td>
<td>7</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>7</td>
</tr>
<tr>
<td>Treatment</td>
<td>8</td>
</tr>
<tr>
<td>Prognosis</td>
<td>9</td>
</tr>
<tr>
<td>Local recurrence</td>
<td>10</td>
</tr>
<tr>
<td><strong>HISTORY OF BREAST CANCER SURGERY</strong></td>
<td>11</td>
</tr>
<tr>
<td><strong>HISTORY OF RECONSTRUCTIVE BREAST SURGERY</strong></td>
<td>14</td>
</tr>
<tr>
<td><strong>QUALITY OF LIFE</strong></td>
<td>14</td>
</tr>
<tr>
<td>AESTHETIC EVALUATION</td>
<td>17</td>
</tr>
<tr>
<td>SPECIFIC AIMS OF THE THESIS</td>
<td></td>
</tr>
<tr>
<td>PATIENTS AND METHODS</td>
<td>18</td>
</tr>
<tr>
<td>Paper I</td>
<td>19</td>
</tr>
<tr>
<td>Paper II</td>
<td>20</td>
</tr>
<tr>
<td>Paper III</td>
<td>20</td>
</tr>
<tr>
<td>Paper IV</td>
<td>21</td>
</tr>
<tr>
<td><strong>STATISTICAL METHODS</strong></td>
<td>21</td>
</tr>
<tr>
<td>RESULTS</td>
<td>23</td>
</tr>
<tr>
<td>Paper I</td>
<td>23</td>
</tr>
<tr>
<td>Paper II</td>
<td>25</td>
</tr>
<tr>
<td>Paper III</td>
<td>23</td>
</tr>
<tr>
<td>Paper IV</td>
<td>27</td>
</tr>
<tr>
<td>DISCUSSION</td>
<td>31</td>
</tr>
<tr>
<td>Paper I</td>
<td>31</td>
</tr>
<tr>
<td>Paper II</td>
<td>32</td>
</tr>
<tr>
<td>Paper III</td>
<td>33</td>
</tr>
<tr>
<td>Paper IV</td>
<td>34</td>
</tr>
<tr>
<td>CONCLUSIONS</td>
<td>37</td>
</tr>
<tr>
<td>FUTURE PERSPECTIVES</td>
<td>39</td>
</tr>
<tr>
<td>SWEDISH SUMMARY</td>
<td>41</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>45</td>
</tr>
<tr>
<td>ACKNOWLEDGEMENTS</td>
<td>55</td>
</tr>
</tbody>
</table>
ABSTRACT

Introduction: Despite the introduction of breast conserving surgery, in Sweden mastectomy is still annually recommended to 40–50 % (about 3000) of women with breast cancer. National guidelines state that, in the absence of contraindications, these women should be offered breast reconstruction. Immediate reconstruction has many advantages compared with delayed reconstruction but questions have been raised about the method’s oncological safety and which method is preferable.

Aim: The first aim was to clarify whether it is sufficiently safe oncologically to offer breast cancer patients primary reconstruction with implants. The next aim was to evaluate different techniques for objective evaluation of breast volume and shape. The third and final aim was to compare two different expander implants regarding the number of operations needed to achieve patient satisfaction, and to measure and compare their cosmetic outcomes objectively and subjectively.

Patients and methods: In a long-term follow-up (median 11.5 years) cohort study, 300 representative invasive breast cancer patients operated with primary reconstruction with implants were compared to 300 matched controls operated with mastectomy alone (Paper I). In a pilot study, 25 patients were operated with a new crescent-shaped expander implant and the result was compared with those seen after surgery with traditional expander implants (Paper II). Twelve patients were included, 6 preoperatively and 6 postoperatively, in a methodological analysis comparing five different methods for evaluating the volume and shape of the breast (Paper III). The final study (Paper IV) was a prospective trial evaluating 40 patients, randomised to either a round one-stage permanent expander implant (n=20) or a crescent two-stage implant procedure (n=20). The number of operations needed and the patients’ satisfaction were evaluated and compared by two panels, one of experts and one of lay people. Objective measurement methods for evaluation of volume and contour differences between the breasts were tested. Quality of life was evaluated with the SF-36 health declaration.

Results: There were no significant differences between mastectomy with and without primary reconstruction regarding incidence of local and/or regional recurrences, or time to start of oncological treatment (Paper I). The outcome with the crescent-shaped expander gave an impression of a more naturally shaped breast (Paper II), which was confirmed in the randomized study. Of the patients operated with the one-stage procedure, 70 % had revision surgery. No major differences were seen between the groups regarding quality of life (Paper IV). Volume was estimated significantly better with traditional, simpler methods like plastic casts compared to modern technology like Magnetic Resonance Imaging and three-dimensional techniques, which tended to overestimate volume. Shape could be measured objectively with a two-dimensional technique based on three-dimensional laser scanning (Paper III).

Conclusion: The cohort study with a well-matched control group demonstrates that immediate breast reconstruction with implants can be offered and performed on patients with invasive breast cancer without any negative effect on oncological safety. The two-stage crescent method gave better aesthetic results than the one-stage procedure, which in a majority of the patients failed to be a one-stage method. An easy and simple method like plastic casts gave more accurate measurements of breast volume than advanced techniques. Laser scanning is a new method for objective measurement of shape and symmetry.
## LIST OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCS</td>
<td>Breast conserving surgery</td>
</tr>
<tr>
<td>BMI</td>
<td>Body mass index</td>
</tr>
<tr>
<td>BP</td>
<td>Bodily pain</td>
</tr>
<tr>
<td>BRCA1</td>
<td>Breast cancer susceptibility gene 1</td>
</tr>
<tr>
<td>BRCA2</td>
<td>Breast cancer susceptibility gene 2</td>
</tr>
<tr>
<td>CT</td>
<td>Computer tomography</td>
</tr>
<tr>
<td>DCIS</td>
<td>Ductal carcinoma in situ</td>
</tr>
<tr>
<td>CMF</td>
<td>Cyclophosphamid, 5-fluorouracil and methotrexate</td>
</tr>
<tr>
<td>DIEP</td>
<td>Deep inferior epigastric perforators flap</td>
</tr>
<tr>
<td>DFS</td>
<td>Disease free survival</td>
</tr>
<tr>
<td>DM</td>
<td>Distant metastasis</td>
</tr>
<tr>
<td>ER</td>
<td>Estrogen receptor</td>
</tr>
<tr>
<td>FEC</td>
<td>5-Floururacil, epirubicin and cyclophosphamid</td>
</tr>
<tr>
<td>GH</td>
<td>General health</td>
</tr>
<tr>
<td>HRT</td>
<td>Hormone replacement therapy</td>
</tr>
<tr>
<td>HRQOL</td>
<td>Health related quality of life</td>
</tr>
<tr>
<td>IBR</td>
<td>Immediate breast reconstruction</td>
</tr>
<tr>
<td>ICC</td>
<td>Intraclass correlation coefficient</td>
</tr>
<tr>
<td>KTH</td>
<td>Kungliga tekniska högskolan (Royal institute of technology)</td>
</tr>
<tr>
<td>LABC</td>
<td>Local advanced breast cancer</td>
</tr>
<tr>
<td>LD</td>
<td>Latissimus dorsi</td>
</tr>
<tr>
<td>LR</td>
<td>Local recurrence</td>
</tr>
<tr>
<td>MH</td>
<td>Mental health</td>
</tr>
<tr>
<td>MRI</td>
<td>Magnetic resonance imaging</td>
</tr>
<tr>
<td>NAC</td>
<td>Nipple areola complex</td>
</tr>
<tr>
<td>OC</td>
<td>Oncological centre</td>
</tr>
<tr>
<td>OS</td>
<td>Overall survival</td>
</tr>
<tr>
<td>PF</td>
<td>Physical functioning</td>
</tr>
<tr>
<td>RE</td>
<td>Emotional role functioning</td>
</tr>
<tr>
<td>RP</td>
<td>Physical role functioning</td>
</tr>
<tr>
<td>PR</td>
<td>Progesterone receptor</td>
</tr>
<tr>
<td>PRO</td>
<td>Patient reported outcome</td>
</tr>
<tr>
<td>RR</td>
<td>Regional recurrence</td>
</tr>
<tr>
<td>SF</td>
<td>Social functioning</td>
</tr>
<tr>
<td>SF-36</td>
<td>Medical outcome study 36-item short form</td>
</tr>
<tr>
<td>SIEA</td>
<td>Superficial inferior epigastric artery</td>
</tr>
<tr>
<td>SN</td>
<td>Sentinel node</td>
</tr>
<tr>
<td>3-D</td>
<td>Three-dimensional</td>
</tr>
<tr>
<td>TMG</td>
<td>Transverse musculocutaneous gracilis flap</td>
</tr>
<tr>
<td>TNM</td>
<td>Tumour node metastasis</td>
</tr>
<tr>
<td>TRAM</td>
<td>Transverse rectus abdominis myocutaneous flap</td>
</tr>
<tr>
<td>VT</td>
<td>Vitality</td>
</tr>
</tbody>
</table>
LIST OF PUBLICATIONS

This thesis is based on the following papers, which are referred to in the text by the Roman numerals given below (I–IV):

I. Eriksen C, Frisell J, Wickman M, Lidbrink E, Krawiec K, Sandelin K
Immediate reconstruction with implants in women with invasive breast cancer does not affect oncological safety in a matched cohort study.
Published on line: Breast Cancer Research and Treatment March 15-2011

II. Eriksen C, Stark B
Early experience with the crescent expander in immediate and delayed breast reconstruction.

III. Eriksen C, Nordstrand Lindgren E, Olivecrona H, Frisell J, Stark B
Evaluation of volume and shape of breasts: Comparison between traditional and three-dimensional techniques.

IV. Eriksen C, Nordstrand Lindgren E, Frisell J, Stark B
A prospective randomised study comparing two different expander implants in primary reconstructions for breast cancer.
In manuscript.
INTRODUCTION

Survival in breast cancer is high and today there are about 80,000 women living in Sweden who have a history of breast cancer [1, 2]. However, despite the availability of breast conserving surgery (BCS), removal of the entire breast is still performed in about 40–50% of breast cancer patients and many women fear the surgical trauma and feeling of being mutilated by a mastectomy [3]. The loss of a breast is a psychological and physical traumatic event and influences the quality of life and body image for many women in all ages [4-10]. There is a growing demand for breast reconstruction and we now have the technique and the possibility to offer breast cancer patients this option in the absence of contraindications. The choice between primary and delayed reconstruction has to be made. Immediate breast reconstruction (IBR) has advantages over delayed reconstruction but questions have been raised about oncological safety [11-13].

The main intention in breast reconstruction must be to individualize each reconstructive method to meet patients’ expectations and wishes, always taking oncological aspects into consideration. Traditionally, women with ductal cancer in situ (DCIS) and T1-2 tumours are offered IBR, while those with presumptive radiotherapy or local advanced breast cancer (LABC) are recommended delayed procedures [14-16]. The general opinion has been that delayed reconstruction should be performed not earlier than two years after adjuvant treatment, i.e. after the period with the highest risk of recurrence.

Although several studies indicate that IBR is oncologically safe, many patients and physicians are still uncertain about this method [17-32]. There has been a concern that, due to more extensive surgery with a higher risk of postoperative complications, IBR may delay the oncological treatment. The first aim of this thesis was to evaluate the oncological safety of IBR with implants.

Notwithstanding the development of advanced techniques with microsurgical flap surgery, the majority of women offered IBR still undergo reconstruction with implants [33]. Traditional breast expander implants, round as well as anatomically shaped, have known
drawbacks, such as undesirable fullness of the upper pole and inadequate expansion of the lower pole, often leading to poor ptosis of the reconstructed breast [34, 35].

The next aim of the thesis was to evaluate traditional methods with new 2- and 3-D techniques for objective measurement and evaluation of breast volume and shape.

A crescent-shaped expander especially expanding the lower pole of the breast may be capable of producing a more natural shape [36]. The final aim of the thesis was to evaluate the crescent expander implant and compare its outcome with that of traditional expander implants.
BACKGROUND

Breast cancer

Epidemiology
The incidence of breast cancer varies internationally but in western countries this is the most common female cancer [37, 38]. In Sweden, more than 7000 women are diagnosed with breast cancer annually, which is equivalent to 30% of all female malignancies (Figure 1) [1, 39]. The mean age at diagnosis is 63 years; 18% are younger than 50 years and 4.5% younger than 40 (Figure 2). After rising 1.4% annually in the past few decades, the annual incidence of breast cancer in Sweden has stabilized or even decreased in recent years [1, 39]. However, in many newly industrialized countries the incidence is increasing rapidly with changing lifestyles, indicating environmental changes as important risk factors [1, 40].

Etiology
The etiology of breast cancer is multi-factorial and still not fully known. Hereditary breast cancer is considered to be present in less than 10% of the patients, and of those a mutation in Breast Cancer susceptibility gene (BRCA) 1 or 2 is the cause in 1/3 of the cases [41, 42]. Other risk factors that can influence the development of breast cancer are obesity, alcohol habits, smoking, low parity, late and low childbirth, early menarche, late menopause, hormone replacement therapy and amount of breast tissue [1].

Diagnosis
Today, breast cancer diagnosis is based on a triple diagnostic procedure with clinical examination of the breast, (radiological) mammography/ultrasound and fine-needle aspiration/core biopsy. The sensitivity of this triple procedure is very high, with less than 1% missed cases [43]. Complimentary methods such as magnetic resonance imaging (MRI) can be used.
Numbers of new invasive breast cancer cases in Sweden by year of diagnosis

Year of diagnosis

Numbers of cases


Figure 1

Numbers of new breast cancer cases by age in Sweden 2008

Age at diagnosis

Numbers of cases

20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 >85

Figure 2.

Source Figure 1-2: www.socialstyrelsen.se/statistik/statistikdatabas

Treatment

Sweden has national guidelines for the treatment of breast cancer. Today, primary treatment in most patients is surgery with additional adjuvant therapy, such as chemotherapy, endocrine therapy, radiotherapy and target drugs, administrated as single
therapy or in various combinations [1]. About 60% of the patients are operated with BCS with removal of only the tumour-bearing part of the breast. After BCS, radiotherapy is always recommended in order to reduce the risk of local recurrence and to improve survival [44]. In patients with large tumours, multicentric or inflammatory cancer, mastectomy is recommended. Patients with advanced tumour stage are offered neoadjuvant therapy before surgery [1, 45]. In invasive breast cancer surgery, the operation is always accompanied by a staging procedure in the axilla. Axillary clearance with removal of 10–15 lymph nodes has been replaced by sentinel node (SN) biopsy in node negative patients. SN is the first node in the axilla that drains the breast tumour. Perioperative pathological examination of the SN spares 60–70 % of all breast cancer patients from major surgery in the axilla [46-48].

**Prognosis**

Mortality has been relatively stable or slowly decreasing, with approximately 1500 breast cancer deaths per year in Sweden (Figure 3) [1, 39]. The improved prognosis may be due to a combination of early detection by screening mammography, increased awareness and better treatment [1].

Figure 3.

Source: www.socionetwork.se/statistik/statistikdatabas
The main prognostic factors are the patient’s age and the tumour stage according to the TNM classification, which is based on the size of the primary tumour (T), and the presence of regional lymph node metastases (N) and distant metastases (M) [1, 39, 49]. A retrospective American study, published in 1998, gave the following 10-year survival rates: Stage 0 patients 95%, Stage 1 patients 88%, Stage 2 patients 66%, Stage 3 patients 36% and Stage 4 patients 7% [50]. In Sweden the overall 5-year survival rate in 2007 was 87.8% [1, 39].

**Local recurrence**

Local recurrence (LR) is usually defined as a recurrence of tumour growth in the skin, subcutaneous layer or chest wall in the area of the previous mastectomy or in the remaining breast after BCS. Quality criteria require that LR after breast conserving surgery for invasive cancer should not exceed 15% after 10 years and be less than 10% after mastectomy [51, 52]. More skin-sparing mastectomies do not seem to affect the LR rate [32, 53, 54].

**History of breast cancer surgery**

More than 3500 years ago the ancient Egyptians described breast cancer as an untreatable disease, though attempts at treatment are documented in the Edwin Smith Papyrus [55]. Hippocrates (c.460–377 BC) described breast cancer as a humoural disease, in keeping with his division of the body fluids. He noted that an untreated tumour was black and hard in appearance and eventually penetrated the skin in the form of a black liquid. He also coined the word cancer from *karkinos*, the Greek word for crab. He considered that surgical treatment was considered inappropriate since survival was longer for those who did not undergo surgery [56]. Galen (129–c. 200 AD) also defined breast cancer as a systemic disease; treatment was strictly pharmacological and surgery was considered dangerous [57].

Until the 18th century it was widely accepted that Galen had the last word on breast cancer’s causes and treatments. During the 18th and 19th centuries, a radical period, the humoural theory fell into disrepute and surgery was discussed and reviewed by numerous physicians, such as Hunter, Le Cat and others who sometimes used slightly unorthodox
methods to convince colleagues [58]. A variety of contemporary theories, some more trustworthy than others, linked breast cancer to sexual activity, the harmful effect of coagulated milk and mammary veins constricted by depression. However, unlike their ancient predecessors, the majority agreed that breast cancer was a local disease curable by surgery alone [58]. The advent of anaesthesia, blood transfusion and antimicrobial techniques made radical mastectomy possible. The foremost pioneer in this field was the American surgeon William Halsted (1852–1922), who developed radical mastectomy [59].

In the mid-1900s Bernard Fisher revolutionized cancer treatment with the theory of metastasis. As Hippocrates had hypothesised more than 2000 years earlier, he argued that breast cancer is a systemic disease in which cancer cells are transported within blood and lymphatic fluid, why surgical treatment alone is not sufficient. In 1976, Fisher started a randomised study which showed that BCS in conjunction with radiotherapy was as effective as radical mastectomy alone [60]. The modern approach to breast cancer surgery was born and further developed with the SN biopsy technique [46, 61-64].

Great progress was also being made in oncological treatment such as chemotherapy, radiotherapy, and endocrine therapy; together with the surgical developments, this lay the foundation for the golden standard for breast cancer treatment in the 1980–90s [1].

**History of reconstructive breast surgery**

Radical mastectomy extended life but was a mixed blessing. Patients became disfigured and often had chronic pain. Dr. Halsted considered these side effects “a necessary evil and since the average age was nearly fifty-five years, they were no longer active members of society” [59]. Fortunately, this attitude has changed, leading to the development of reconstructive breast cancer surgery and a focus on quality of life [65].

Historically, the first reconstruction, when V Czerny transferred a lipoma to the breast, was published in 1895 [66]. The first silicone implant was launched by Cronin and Gerow in 1961 and Arion introduced the first saline expander in 1964 [67, 68]. In 1984, Becker further developed the tissue expander, which came into frequent use in the 1990s and served as a permanent implant [69]. Since then, five generations of implants have been developed, with different covers, contents, sizes and shapes.
The most common types of implant used for reconstruction today are textured, anatomically-shaped silicone shells, filled with silicone, saline or a combination of the two (Figure 4) [70].

![Figure 4. Different models of breast implants.](image)

The development of implant-based reconstructions has been accompanied by the introduction of several autologous methods. An autologous technique involves transferring tissue to the site of the removed breast, either as a pedicled flap or with microsurgical technique as a free flap. The most common donor sites are the abdomen, the back or the gluteal region. In general, autologous breast reconstruction is more demanding than implant-based reconstruction resulting in larger incisions, more scars, longer operating time and more complications. On the other hand, in the longer run the aesthetic result may be better for some patients [71, 72].

A commonly used reconstructive technique is the latissimus dorsi (LD) flap, popularized in the 1970s [73-75]. The flap is tunneled under the skin to the mastectomy site as a pedicled flap, sometimes combined with an implant to obtain the desired volume. The LD flap can also be used alone as an extended flap, with fatty tissue harvested together with the muscle [76]. The lateral thoracodorsal flap, also known as the “Göteborg” flap, is a fasciocutaneous flap added from the lateral-dorsal thoracic wall to form the lateral part of the breast. This technique is also frequently combined with implants [77].
The transverse rectus abdominis myocutaneous flap (TRAM) was introduced for breast reconstruction in the 1980s; it can be either pedicled or used as a free flap [78, 79, 80]. Today, the free TRAM is often replaced by perforator flaps, such as the deep inferior epigastric perforator (DIEP) flap or the superficial inferior epigastric artery (SIEA) flap [81-84]. With these flaps, the muscle and fascia do not have to be removed from the abdomen. Only the skin, the subcutaneous tissue and the vessels are transferred, which has proved to be advantageous for the patients in terms of decreased donor-site morbidity and quicker recovery [85]. Alternatives are the free gluteal flap [86], the free anterolateral thigh flap [87] and the free transverse musculocutaneous gracilis (TMG) flap [88].

Ongoing development of new techniques, such as acellular dermal matrix for use in the lower pole of implant reconstructions, and refinement of older methods, such as lipofilling, creates new possibilities in the area of reconstructive breast surgery [76, 89, 90].

The choice of a reconstructive method is a multifactorial issue. Primary versus delayed? Implants versus autologous tissue, or a combination? Oncological considerations, local traditions, the patient’s condition and preferences will influence the decision. Local access to professional competence for reconstruction may also affect the choice between IBR and a delayed procedure. Breast reconstructions were first performed as a delayed procedure by plastic surgeons. The number of IBR has increased in recent years and so has the number of breast surgeons performing reconstructive oncoplastic breast surgery. Cooperation between breast and plastic surgeons at major breast centres has made IBR more accessible. However, the proportion of breast cancer patients who undergo IBR in Sweden is only 6 % [91].
**Quality of life**

The concept of health-related quality of life (HRQOL) comprises a wide range of aspects with a variety of definitions, mostly focusing on physical functioning, mental health, social, emotional and sexual wellbeing in relation to a medical condition and treatment [92, 93].

Breast cancer survivors is a growing group of women who desire excellent treatment and a good quality of life. The breast is involved in many women’s expectations regard to body image, breastfeeding and sexual aspects, for instance. The feeling of being mutilated and unattractive is still a big issue for many women, especially those facing mastectomy. The aim of breast reconstruction is to improve these patients’ HRQOL [94-97].

Breast cancer surgery does affect women’s body image and many questionnaires have been developed for patient-reported outcomes (PRO). Only a few have been validated and specifically address breast cancer surgery with the ability to measure the individual patient’s outcome. The choice of surgical procedure to recommend with reference to HRQOL is a difficult decision [93, 98].

One must not forget that whichever method is chosen for breast reconstruction, the procedure inevitably involves more physical trauma than mastectomy alone. A fair number of women choose not to have a breast reconstruction which can be an excellent choice for a high quality of life, depending on the patient’s preferences [99].

**Aesthetic evaluation**

An objective method for evaluation makes it possible to set standards and thereby compare and evaluate the aesthetic results of different surgical techniques. Many attempts have been made to objectively evaluate breast shape, volume and contour, both before and after surgery. These evaluations involve volume measurement by MRI, computed tomography (CT), mammography, water displacement, plastic cups or thermoplastic casts and assessment of shape and symmetry by anatomical measurement and three-dimensional (3-D) techniques (Figure 5) [100-108]. There is now a wide variety of reconstructive methods and a constant development, which makes objective evaluation for comparison of results even more important. The results of breast reconstruction can be evaluated objectively and
subjectively. Subjective evaluation comprises the patient’s satisfaction or a jury’s assessment of patient images; this can be a problem since the results are based on people’s opinions in accordance with their expectations. A patient may be very unsatisfied with a result that is “perfect” from a surgeon’s point of view. On the other hand, a surgeon may find a result poor even when the patient is very satisfied (Figure 6, 7 a-c).

Figure 5. Postoperative 3-D laser scan imaging.
Figure 6. Result after IBR with an anatomical expander on the left side and a mastopexy on the right side. This patient was very satisfied with the result despite of the upper pole fullness seen in figure 6 b.

Figure 7. Postoperative result after a two stage reconstruction on the left side and a breast reduction on the right side. This patient was very dissatisfied while the surgeon rated the result as very good.
SPECIFIC AIMS OF THE THESIS

- To analyse long-term results of IBR with implants with regard to local, regional and distant recurrences and survival compared to women operated with mastectomy alone. To study whether IBR affects time to postoperative adjuvant treatment.

- To evaluate a consecutive group of patients having immediate or delayed breast reconstruction with a new crescent-shaped expander and to compare the results with patients operated with round or anatomically-shaped expander implants.

- To define the most reliable method for objective evaluation of breast volume and shape, pre- and postoperatively, in breast cancer patients undergoing primary breast reconstruction with implants.

- To evaluate the crescent-shaped two-stage expander method with a traditional permanent round expander implant and to compare this, using objective measurements, including 3-D laser scanner, with subjective evaluation of the aesthetic outcome.
PATIENTS AND METHODS

Flow chart of patients included in the thesis

Retrospective matched cohort
n=775

- Excluded
  n=175

  IBR
  n=300

  Controls
  n=300

Paper II (2002–03)
Pilot study
n=95 (98 breasts)

- Round/anatomical expanders
  IBR
  n=33

- Crescent expander
  IBR
  n=14

  Delayed
  n=37

  Delayed
  n=11 (14 breasts)

Paper III (2004–10)
Methodological study
n=12

- Preoperative
  n=6

- Postoperative
  n=6

Paper IV (2004–10)
Prospective randomised study
n=70

- One-stage (Becker-25)
  n=20

- Two-stage (Crescent)
  n=20

Excluded
lost to follow-up
n=30

n=37

n=11

n=33

n=14
In a retrospective cohort study, 475 consecutive patients with primary breast cancer were operated with IBR with implants. The patients had been registered prospectively in a separate database and only those with invasive breast cancer with a follow-up of at least 4 years were included (n=300). This cohort of patients was matched with women from the Regional Breast Cancer Register of Stockholm-Gotland who had been operated with mastectomy without IBR. Each case in the IBR group was matched with one control in terms of age, tumour size, nodal status and year of operation, with a median follow-up of 11.5 years.

All patients were discussed pre- and postoperatively at the multidisciplinary team conference. Patients with inflammatory breast cancer or tumours adhering to the pectoral muscle or skin were not offered IBR, neither were women with high body mass index (BMI) or heavy smokers, as they were considered to be unsuitable for implant reconstruction. Patients with large tumours, neo-adjuvant chemotherapy and planned for postoperative radiotherapy were included, while those reconstructed after earlier ipsilateral breast cancer were classified as LR and excluded from the study.

Mastectomy was performed with earlier scars (if BCS was not radical) and the nipple-areola complex (NAC) excised and with the inner blade of the pectoral fascia left intact. The SN biopsy technique was introduced in 1998 and gradually replaced axillary clearance in node negative patients. All women in the IBR group were operated with permanent or expandable implants placed submuscularly to achieve full muscle cover.

Oncological treatment was based on recommendations and guidelines from the Stockholm Cancer Study Group.

The patients were followed for a total of 5 years at the Oncological Department. Patients with no sign of recurrences were then referred to the general practitioners for further follow-up. The patients in the IBR group were followed separately at the Department of Reconstructive Surgery for evaluation and further assessments.

Variables from clinical records were registered and patients were followed until the end of June 2008. Type of breast cancer, Elston grade [109, 110], hormonal status, time to oncological treatment, type of chemotherapy, radiotherapy and early complications were
registered, as were incidence of recurrences, time to detection, how the recurrences were detected and survival. The results were compared with data from the Oncologic Centre (OC) in Stockholm and from the National Cause of Death Register.

**Paper II**

In a pilot study, 25 breast cancer patients were operated with a new crescent-shaped expander implant; bilateral reconstruction was performed in three of them. Further, medical records were reviewed in 70 patients operated with round or anatomically shaped expander implants. The crescent expander has a magnetic filling port incorporated in the centre of the implant, while the traditional expander has a separate filling port placed subcutaneously. Forty-seven patients were operated with IBR and 48 patients had delayed procedures. Nine (36 %) of the patients operated with the crescent-shaped expander received radiotherapy compared to 12 (17 %) patients in the other group. Data concerning adjuvant treatment, complication rate, fullness of the upper pole, the necessity of revision, and the patient’s satisfaction were recorded.

**Paper III**

From the prospective randomised trial (paper IV) evaluating two different implants in IBR, 12 patients were selected for this study and divided into two groups. Breast volume and shape were evaluated in six patients preoperatively and in another six postoperatively.

Breast volume was measured in the preoperative group using standardized plastic cups, thermoplastic cast material, MRI and 3-D laser scanner. Contour/shape was evaluated with a two-dimensional technique based on 3-D laser scan imaging (Figure 8 a, b). The same procedures were used for patients in the postoperative group and in addition, volume was assessed with another 3-D analysis based on stereophotographic images. The mastectomy specimen was measured by fluid displacement in ml (Archimedes’ principle) and by weight in grams and served as a control for the volume measurements. For evaluation of shape, the opposite healthy breast served as a reference.

Figure 8. (a) Sagittal sections in 3-D laser scan imaging.
(b) Contour differences between the breasts.


**Paper IV**

In order to compare two different expander implants, a prospective randomised study was designed. Power estimation was based on experience from paper II and 40 patients were needed. Breast cancer patients scheduled for IBR with implants were eligible for participation. Seventy patients were included in the study, 40 patients (20 in each group) were evaluated, while 30 patients were lost to follow-up. Patients were randomised to either a one-stage round permanent expander (Becker 25) featuring a separate filling port, or a two-stage crescent-shaped expander (McGhan 133 LV) with an integrated magnetic filling port, replaced in a second stage by an anatomical silicon implant.

Preoperatively, jugulum-nipple distance and ptosis (cm) were recorded. Breast base width was measured with a rigid measurement device. Breast volume was measured using standardised plastic cups and thermoplastic sheet material (Orfit); photographic images were obtained.

All patients were operated by a standard mastectomy. The mastectomy specimen was measured by Archimedes’ principle in millilitres and by weight in grams. The number of operations, additional revision surgery and complications in the two groups were documented. Postoperatively, the patients were measured in the same way as preoperatively and additionally by a 3-D laser scanner and two-dimensional evaluation of contour differences between the breasts. The patient’s satisfaction regarding shape, volume and symmetry was recorded on a scale from 1–6 (1=very bad, 6=very good). Two panels, one of experts and one of lay people, evaluated the aesthetic results on the same scale and their assessments were compared with the patient’s satisfaction. Postoperatively, the expert panel also evaluated indication for further revision surgery in the one-stage group. Quality of life was evaluated with SF-36 (Short Form medical outcome) a validated health declaration; 36-item, before and after surgery.

**Statistical methods**

*Paper I:* The McNemar test and the Stuart-Maxwell test were used for pairwise comparison of categorical variables. When pairwise comparison was not appropriate, Person’s chi-square test for categorical variables and the Mann-Whitney-Wilcoxon test for continuous
variables were performed. The Kaplan-Meier method was used to calculate disease-free survival as well as breast cancer specific survival. Hazard ratios and 95% confidence intervals were estimated with the Cox proportional hazard regression model with stratification on the matched pairs. All statistical analyses were performed in STATA/IC statistical software, version 10.0.

**Paper III:** Paired $t$-test and repeated ANOVA were used to evaluate whether there were significant differences between the methods. Pairwise comparisons were made, and the Bonferroni connection applied. The validation of the MRI and the three-dimensional methods was tested by intraclass correlation coefficient (ICC).

**Paper IV:** Before the study, a power analysis indicated that a total of 40 patients was needed, with 20 in each group, based on a one-sided test alpha=0.05 and a power 1-beta=0.90, $\Pi_1=0.25$ and $\Pi_2=0.70$. Fisher’s exact test was used for calculation of significance, comparing the revision rate in the one-stage and two-stage groups. Tests were significant at $p < 0.0500$. Variables were summarized using standard descriptive statistics such as frequencies, means, medians and standard deviations. Sign-tests were applied for comparison of patient-based data before and after revision surgery in the one-stage group. Mann-Whitney U-tests were applied for evaluation of patients’ final scores between the two groups. The kappa-statistic measure of agreement was used to analyse the agreement in the indication for revision surgery in the expert group (0.0=poor, 0.81–1.00=almost perfect). Paired and unpaired $t$-tests were used to analyse differences between the groups in the SF-36 health declaration.
RESULTS

**Paper I**

The two groups were well matched and comparable, with small differences. The median tumour size was 19 and 20 mm; node positive disease was present in 36% and 36.7%; further clinical and histopathological characteristics are presented in (Table I).

<table>
<thead>
<tr>
<th></th>
<th>IBR n = 300</th>
<th>Controls n = 300</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median, years</td>
<td>48</td>
<td>48</td>
<td></td>
</tr>
<tr>
<td>Range, years</td>
<td>23-70</td>
<td>28-69</td>
<td></td>
</tr>
<tr>
<td><strong>Tumor size (mm)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median, Range</td>
<td>19</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>0-100</td>
<td>0-90</td>
<td></td>
</tr>
<tr>
<td><strong>Lymph nodes (%)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>64.0</td>
<td>63.3</td>
<td></td>
</tr>
<tr>
<td>1-3</td>
<td>23.0</td>
<td>22.0</td>
<td></td>
</tr>
<tr>
<td>≥4</td>
<td>13.0</td>
<td>14.7</td>
<td></td>
</tr>
<tr>
<td><strong>Morphology (%)</strong></td>
<td></td>
<td></td>
<td>0.003¹</td>
</tr>
<tr>
<td>Ductal</td>
<td>n = 291</td>
<td>n = 283</td>
<td></td>
</tr>
<tr>
<td></td>
<td>66.3</td>
<td>79.9</td>
<td></td>
</tr>
<tr>
<td>Lobular</td>
<td>27.2</td>
<td>16.2</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>6.5</td>
<td>3.9</td>
<td></td>
</tr>
<tr>
<td><strong>Hormone receptor status (%)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ER +</td>
<td>n = 274</td>
<td>n = 287</td>
<td>0.003²</td>
</tr>
<tr>
<td></td>
<td>79.9</td>
<td>68.6</td>
<td></td>
</tr>
<tr>
<td>PR +</td>
<td>n = 251</td>
<td>n = 275</td>
<td>0.008²</td>
</tr>
<tr>
<td></td>
<td>71.3</td>
<td>61.1</td>
<td></td>
</tr>
</tbody>
</table>

Table I. Patients’ clinical and histopathological characteristics.

Immediate breast reconstruction (IBR), estrogen receptor (ER), progesterone receptor (PR),
¹Stuart-Maxwell test, ²McNemar chi-square test.

Lobular cancers and hormone receptor-positive tumours were more prevalent in the IBR group and the patients in this group more often received endocrine treatment. There were no significant differences between the two groups in the proportion of patients treated with neoadjuvant chemotherapy, in those receiving adjuvant chemotherapy or in those receiving postoperative radiotherapy. Furthermore, no differences were seen between the two groups in early postoperative complication rates or in time to initiate oncological treatment (Table II).
In the analysis of first events, the incidence of all recurrences was 28.4% in the IBR group and 32.8% in the control group. There were no significant differences in either local recurrences in the breast (8.2% in the IBR group, 9.0% in the control group) or in the regional recurrence rate (8.2% and 9.7%, respectively), while distant metastases were significantly more frequent in the control group (20.3% and 27.1%, respectively), p=0.049. The mean time to detection of local recurrence was 1.3 years in the IBR group versus 2.2 years in the control group (Table III). The majority of local recurrences were detected by clinical examination (94%); there were no significant differences between the two groups in the detection of either regional recurrences or distant metastases. The IBR group had a longer survival time; the differences in breast cancer mortality and all-causes mortality were statistically significant.

<table>
<thead>
<tr>
<th></th>
<th>IBR n = 300</th>
<th>Controls n = 300</th>
<th>p-value&lt;sup&gt;1&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neoadjuvant chemotherapy (%)</td>
<td>13.0</td>
<td>15.7</td>
<td>0.346</td>
</tr>
<tr>
<td>Adjuvant chemotherapy (%)</td>
<td>45.2</td>
<td>47.6</td>
<td>0.431</td>
</tr>
<tr>
<td>Completed chemotherapy (%)</td>
<td>94.3</td>
<td>92.4</td>
<td>0.569&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
<tr>
<td>Time to chemotherapy (weeks)</td>
<td>n = 112</td>
<td>n = 105</td>
<td>0.376&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
<tr>
<td>Median</td>
<td>5.0</td>
<td>5.1</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>2-22</td>
<td>2-33</td>
<td></td>
</tr>
<tr>
<td>Hormonal treatment (%)</td>
<td>n = 283</td>
<td>n = 273</td>
<td>0.103</td>
</tr>
<tr>
<td>Radiotherapy (%)</td>
<td>n = 289</td>
<td>n = 284</td>
<td>0.825</td>
</tr>
<tr>
<td>Time to radiotherapy (weeks)</td>
<td>n = 86</td>
<td>n = 70</td>
<td>0.902&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
<tr>
<td>Median</td>
<td>24.1</td>
<td>24.7</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>6-48</td>
<td>5-42</td>
<td></td>
</tr>
<tr>
<td>Complications &lt; 30 days (%)</td>
<td>7.3</td>
<td>6.3</td>
<td>0.622</td>
</tr>
</tbody>
</table>

Table II. Oncological treatment, time to treatment and complications. Immediate breast reconstruction (IBR), <sup>1</sup> McNemar chi-square test unless otherwise stated, <sup>2</sup> Person’s chi-square test for categorical variables; Mann-Whitney-Wilcoxon test for continuous variables.)
Table III. Incidence, detection mode and time to detection of recurrence.

Immediate breast reconstruction (IBR). ¹ McNemar chi-square unless otherwise stated,
(² Person's chi-square test for categorical variables; Mann-Whitney-Wilcoxon test for continuous variables).

<table>
<thead>
<tr>
<th></th>
<th>Total number of events</th>
<th>First event</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IBR</td>
<td>Controls</td>
</tr>
<tr>
<td>Overall recurrence (%)</td>
<td>28.4</td>
<td>32.8</td>
</tr>
<tr>
<td></td>
<td>8.2</td>
<td>9.0</td>
</tr>
<tr>
<td></td>
<td>0.2-11.9</td>
<td>0.5-11.6</td>
</tr>
<tr>
<td>Local recurrence (%)</td>
<td>8.2</td>
<td>9.7</td>
</tr>
<tr>
<td>Time to detection (years)</td>
<td>1.3</td>
<td>2.2</td>
</tr>
<tr>
<td></td>
<td>0.2-11.9</td>
<td>0.5-11.6</td>
</tr>
<tr>
<td>Regional recurrence (%)</td>
<td>8.2</td>
<td>9.7</td>
</tr>
<tr>
<td>Time to detection (year)</td>
<td>4.8</td>
<td>1.6</td>
</tr>
<tr>
<td></td>
<td>0.1-12.5</td>
<td>0.3-11.0</td>
</tr>
<tr>
<td>Distant metastases (%)</td>
<td>20.3</td>
<td>27.1</td>
</tr>
<tr>
<td>Time to detection (year)</td>
<td>2.7</td>
<td>3.3</td>
</tr>
<tr>
<td></td>
<td>0.0-12.4</td>
<td>0.0-13.9</td>
</tr>
</tbody>
</table>

Paper II

Of the 70 patients operated on with round or anatomically shaped expanders, 61 (87%) were dissatisfied with the aesthetic result. The main reason for this was asymmetry of form caused by fullness of the upper pole of the reconstructed breast. The patient's dissatisfaction led to reoperation with an anatomically-shaped permanent implant in 74% (52/70). Patients operated with the crescent-shaped expander were followed for a mean of 8 (4–15) months; replacement of the crescent expander with a form-stable anatomical implant was performed 6–8 months after the primary operation. Of the 25 patients operated with the crescent procedure, four developed complications. In 23 reconstructions the aesthetic result with the crescent-shaped expander was rated as good/very good by the patients.

Paper III

The peroperative volume of the resected breast measured according to the Archimedes principal correlated well with its weight (p=0.64) and was defined as the true volume of the breast. Statistically significant differences were detected when MRI, 3-D and plastic cups were compared with the Archimedes method. In contrast, no significant difference was detected between plastic casts (Orfit) (p=0.17) and the Archimedes method.
Validations of the volume calculations with the MRI and 3-D methods also showed high correlations between the observers in terms of ICC.

For the postoperative group, the correlations between the results from five different measuring methods are shown in Figure 9. As with the preoperative group, the MRI and 3-D techniques showed statistically significantly larger volumes than the traditional methods. Individual differences between the breasts was not detected ($p=0.63$).

![Figure 9. The correlation between five different methods of volume measurement](image)

The differences in contour showed larger discrepancies between the breasts in postoperative patients than in the unoperated women in the preoperative group (Figure 10).

![Figure 10. The differences in contour between the breasts expressed in mm, A= preoperative and B= postoperative group.](image)
Paper IV

Forty women (20 in each group), out of the 70 included, completed the study and were followed for a median of 3.5 (range 1.5–5) years after the primary operation. The mean time for completing the reconstruction was 18.8 months in the one-stage group and 20.5 months in the two-stage group. Age, BMI and volume of the resected breasts were comparable in the two groups.

In line with our results in paper III, the best correlation for volume was seen with the plastic casts method (Orfit), while the 3-D volume measurements were too high. The final volume of the reconstructed breasts and filling frequencies did not differ statistically between the groups. A majority of the patients in both groups (17 out of 20) underwent breast reduction/mastopexy of the contralateral breast.

In the one-stage group, 14 out of 20 (70%) women were not satisfied with the aesthetic result compared to 2 out of 20 (10%) women in the two-stage group. This difference between the groups in terms of corrective surgery was highly significant, p= 0.0002. The 14 unsatisfied patients in the one-stage group underwent a capsulotomy/ectomy and replacement of the permanent expander implant with a form-stable implant. Additional abdominal advancement was performed in eight of these patients in order to create a better definition of the inframammary fold and ptosis. Three of the patients also had augmentation on the contralateral side to achieve symmetry. Moreover, 3 of these 14 patients required a third operation because of asymmetries when the final outcome was evaluated at follow-up. The two patients in the two-stage group had corrective surgery because of an unduly large implant in one case and a too lateral placement of the implant in the other. The two-dimensional calculations of the upper and lower poles between the breasts demonstrated better symmetry in the two-stage group. The expert panel disagreed with the indication for revision surgery in 2 of the 14 patients who had revision in the one-stage group. Plastic surgeons considered that the main issue for corrective surgery was upper pole fullness and poor ptosis, which was in line with our objective two-dimensional analysis.
The complication rate was low among the 40 evaluated patients. Two seromas with superficial infections occurred in the one-stage group compared to one in the two-stage group and could be cured with aspiration and oral antibiotics.

The patients’, the expert and lay people panels all gave high scores for the final aesthetic results. The patients were most satisfied, followed by the experts and then the lay people. The lowest scores were seen in the one-stage group before revision. Statistically significant differences (p<0.005) in patient satisfaction before and after corrective surgery were found in the one-stage group for the parameters shape, size, symmetry and patient’s overall aesthetic result (Figure 11).

![Figure 11. Patient’s opinion regarding aesthetic outcome (rated 1-6, 1=very bad, 6=very good).]
Pre- and postoperative SF-36 scores for both groups and an age-adjusted reference norm group are presented in Figure 12. Compared to the norm group, the scores for bodily pain were higher in both groups. The scores for the last three domains measuring emotional well-being were statistically significantly lower preoperatively in both groups compared to the norm group. At follow-up, the study groups had statistically significantly improved their scores and the score for bodily pain remained higher. Postoperatively, the two-stage group showed a higher level for emotional role functioning but the difference was not statistically significant.

Figure 12. SF-36 health profile comparing pre and postoperatively results from both groups compared to aged matched norm group. Pre.op = preoperatively, post.op = postoperatively. Norm group=Ref.group. PF= physical function, RF= physical role functioning, BP= bodily pain, GH=general health, VT= vitality, SF= social functioning RE= emotional role functioning, MH= mental health.
DISCUSSION

**Paper I**

To the best of my knowledge, no prospective randomized studies have been published that address IBR’s oncological safety. There are several retrospective studies regarding IBR and the rate of LR but just a few of them are cohort studies with a controlled design (Table IV) [16, 17, 19, 20, 23, 25, 28, 30, 31, 53, 111-114].

<table>
<thead>
<tr>
<th>References</th>
<th>Tumour stage</th>
<th>Study period</th>
<th>Number of patients / control group</th>
<th>Follow-up (month)</th>
<th>Local recurrences / control group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Johanson et al, 1989</td>
<td>0-III</td>
<td>1980-86</td>
<td>118</td>
<td>28</td>
<td>6.7%</td>
</tr>
<tr>
<td>Noone et al, 1994</td>
<td>0-III</td>
<td>1979-88</td>
<td>306</td>
<td>76</td>
<td>3%</td>
</tr>
<tr>
<td>Slavin et al, 1994</td>
<td>1-IV</td>
<td>1982-90</td>
<td>161</td>
<td>65</td>
<td>11%</td>
</tr>
<tr>
<td>Ringberg et al, 1999</td>
<td>I-III</td>
<td>1980-94</td>
<td>79</td>
<td>43</td>
<td>5%</td>
</tr>
<tr>
<td>Kroll et al, 1999</td>
<td>I-II</td>
<td>1986-90</td>
<td>154</td>
<td>72</td>
<td>7%</td>
</tr>
<tr>
<td>Vanderweyere et al, 2000</td>
<td>0-IV</td>
<td>1990-95</td>
<td>49 / 49</td>
<td>72</td>
<td>4.1% / 2.0%</td>
</tr>
<tr>
<td>Medina Franco et al, 2002</td>
<td>I-IV</td>
<td>1986-97</td>
<td>173</td>
<td>73</td>
<td>4.5%</td>
</tr>
<tr>
<td>Langstein et al, 2003</td>
<td>-----</td>
<td>1988-98</td>
<td>1694</td>
<td>96</td>
<td>2.3%</td>
</tr>
<tr>
<td>Carlson et al, 2003</td>
<td>0-IV</td>
<td>1989-98</td>
<td>565</td>
<td>65</td>
<td>5.5%</td>
</tr>
<tr>
<td>Sandelin et al, 2004</td>
<td>I-III</td>
<td>1990-96</td>
<td>203</td>
<td>60</td>
<td>6.5%</td>
</tr>
<tr>
<td>Greenway et al, 2005</td>
<td>I-II</td>
<td>1984-04</td>
<td>225</td>
<td>49</td>
<td>1.7%</td>
</tr>
<tr>
<td>Petit et al, 2008</td>
<td>I-III</td>
<td>1997-01</td>
<td>518 / 159</td>
<td>70</td>
<td>5.2% / 9.4%</td>
</tr>
<tr>
<td>Erikson et al, 2011</td>
<td>I-III</td>
<td>1988-06</td>
<td>300 / 300</td>
<td>138</td>
<td>8.2% / 9.0%</td>
</tr>
</tbody>
</table>

Table IV. Local recurrences after immediate breast reconstruction, previously published studies.

In order to evaluate whether a reconstructive procedure could influence the oncological outcome, a retrospective cohort study was designed in which patients with invasive breast cancer undergoing IBR with implants were compared with a matched group of women operated with mastectomy alone. Its strength lay in the well-matched and representative patient material and the long follow-up (median 11.5 years). The study provides evidence that IBR with implants can be considered a safe procedure oncologically. No significant inter-group differences were found in the rates of local recurrence and regional recurrence, neither were there any differences in time to initiate adjuvant treatment, number of chemotherapy cycles, radiotherapy treatment or in detection mode for recurrences. The rate of distant metastases was significantly higher in the control group and the survival figures were better for the reconstructed group. These results are in line with other studies, possibly as a consequence of confounding factors such as socioeconomic status and selection bias in
inclusion criteria, as IBR was usually not recommended for overweight patients and smokers [30, 115]. One limitation was that although the two groups were well-matched, the IBR group included more lobular cancers and a higher proportion of hormone receptor-positive tumours, which could indicate an overrepresentation of favourable tumours and thereby better prognosis in the IBR group. On the other hand, lobular carcinoma does not have a better clinical outcome or survival rate compared with ductal carcinoma [116]. A statistical correction for hormonal receptor status did not alter the results regarding recurrences, but the difference in breast cancer mortality risk was no longer significant.

There are few prospective studies concerning the aesthetic advantages and disadvantages of IBR with and without irradiation and which alternative can be favourable in the long run. In our experience, IBR with implants can be combined with irradiation from an oncological point of view but the aesthetic results tend to be inferior compared to non-irradiated reconstructions [117-123]. Many authors favour autologous tissue reconstructions. However, these techniques are less well investigated regarding oncological safety and especially as immediate procedures. Moreover, complications are liable to be more frequent and might delay adjuvant treatment [12, 13, 124]. As a guide in decision-making, SN biopsy (pre- and peroperative) and core biopsy can be used to predict the need for postoperative adjuvant therapy [124, 125].

A review article on oncological aspects of breast reconstruction in 2005 concluded that there was a lack of high-quality evidence on how to advise women considering IBR and IBRs possible impact on adjuvant treatment and prognosis [12]. Since then, three long-term retrospective follow-up studies with controls, two of them with matched controls (including paper I) have been published together with two review articles all pointing in the same direction. IBR with implants can safely be offered to breast cancer women in the absence of contraindications [29-32].

**Paper II**

This paper was an early evaluation of the crescent-shaped expander implant that had been introduced on the market just before. Patients operated with this new breast expander, in immediate as well as in delayed reconstructions, expressed great satisfaction with the reconstructed breast after expansion. However, most expander implants designed for a one-stage procedure failed to meet the patient's expectations since in most cases a satisfactory
result required more than one operation. Unfortunately, the crescent-shaped expander could not be used as a permanent implant because of the configuration of the central magnetic filling port, which is made of metal and could interfere with MRI investigation. In contrast to traditional filling ports, we did not encounter problems as rotation, pain, or difficulties in localising the port. The results suggested that, compared to round and anatomically shaped expanders, the crescent-shaped expander gave a more natural shape, with less fullness of the upper pole and good ptosis. To find out whether or not these results could be verified, a methodological study (paper III) and a prospective randomised study (paper IV) were designed.

**Paper III**

A methodological study was designed to evaluate new objective 3-D methods for measuring breast volume and shape and to compare them with traditional techniques.

Collaboration was initiated with Professor Stefan Jonson at the Royal Institute of Technology (KTH) and photographers at the Department of Medical Imaging, Karolinska University Hospital. The idea was to create 3-D images based on stereo photographs and to produce a new program for calculating breast volume and shape. This unfortunately proved much more difficult than expected and did not come about. Meanwhile a private company (Alicona) gave us permission to calculate breast volume from stereophotographs of six patients’ images using the 3-D MeX computer program. The calculated results from the 3-D MeX program were compared with MRI, plastic casts and cups, and a 3-D laser scanner (acquired by Karolinska University Hospital in 2009). Compared to 3-D laser scan, the 3-D MeX method gave a slightly better correlation with the true values of breast volume, possibly because this method was more sensitive in recognising the convexity of the thoracic wall.

Earlier tests of the accuracy and reproducibility of 3-D evaluation have indicated a good potential. Our data suggest, however, that the method’s accuracy as regards aspects of volume is questionable [104].
The findings confirmed that the method with plastic casts was easy to perform, delivered high accuracy and was inexpensive as the same material could be used for several evaluations. The plastic cups may be useful for estimating the volume of the female breast as data were in fairly good agreement with the true volume.

Traditional methods gave little or no information about the shape or contour of the breast. A two-dimensional sagittal section from 3-D images produced a contour of the breasts, permitting a numerical calculation of differences between their upper and lower poles. Numerical 3-D differences between the breasts could also be calculated with the Geomagic software program but such 3-D calculations could not be obtain that were reproducible. This may have been due to the complexity of the program, which had just been introduced at the Department of Medical Imaging. This could be a promising method for future studies. The introduction of 2- and 3-D scanning techniques added new dimensions to the evaluation of shape and volume but the data on volume should be interpreted with caution.

**Paper IV**

Various types of breast implants have been developed and evaluated in recent years. The overall aim of reconstructive surgery in breast cancer patients has been to improve the patient’s quality of life and satisfaction with the outcome, using as few operations as possible [3, 7, 8, 92-95].

The main problems with traditional implants, both round and anatomically shaped, have been the occurrence of upper pole fullness and a lack of ptosis, while the crescent-shaped implant seemed to be capable of conferring a more natural shape [36]. A prospective randomised study was designed to determine to what extent the round Becker 25 expander implant could meet patients’ expectations as a one-stage procedure compared with the two-stage crescent-shaped expander.

The strength of this study was its randomised design with two groups that were comparable regarding age, BMI and breast volume. Another strength was that the aesthetic outcome was evaluated on the basis of both objective and subjective data.
The results confirmed that the round permanent expander implant could not meet neither the patients’ nor the surgeons’ expectations as a one-stage procedure; the difference between the two groups in the number of reoperations was highly statistically significant. These results demonstrated the necessity of a two-stage procedure for achieving a good aesthetic outcome. The patients in the one-stage group were subjected to more advanced secondary surgery than those in the two-stage group, for whom abdominal advancement and augmentation were not required to achieve a satisfactory result.

The data further showed that patients in the two groups were equally satisfied with the final results after corrective surgery, except that final symmetry was significantly better in the two-stage group. The patients expressed the greatest satisfaction, followed by the experts and then the lay people.

In this study we also evaluated quality of life pre- and postoperatively in both groups and compared the results with an age-related reference group. Both groups scored higher on physical functioning and bodily pain than the reference group, which was in line with other studies and to be expected [126, 127]. The present data indicated that both groups recovered well from the low preoperative scores for emotional well-being and vitality. The two-stage group experienced better emotional role functioning than the one-stage group but the number of patients was too small to establish statistical significance.
CONCLUSIONS

- In the absence of contraindications, immediate breast reconstruction with implants can be offered to and performed on patients with invasive breast cancer without any negative effect on oncological safety.

- Low-cost plastic cast measurement gave more exact values for breast volume than various methods for 3-D measurement. However, more advanced 3-D technology may prove to be an important and useful technique for the objective evaluation of reconstructive breast surgery. Shape can be measured objectively by two-dimensional technique based on 3-D laser scanning.

- The round permanent expander method failed to serve as a one-stage procedure, mostly due to upper pole fullness and lack of ptosis. The crescent two-stage expander method gave a more natural shape of the breast; both the patients and the panels of experts and lay people scored highest for shape and symmetry. Quality of life was significantly improved 1.5 years postoperatively in both groups, with no major differences between the groups.
This thesis is based on clinical questions raised in a breast surgeon’s daily work with breast cancer women in need of a mastectomy.

Early studies showed that a mastectomy left 30 % of the women with problems of reduced self-esteem, depression, poor sleep and increased anxiety [128]. National guidelines state that in the absence of contraindications, these women should be offered breast reconstruction. Both IBR and delayed reconstruction are slowly being used more frequently. Despite the advantages of IBR, a majority of reconstructions are performed as a delayed procedure. The trend is not uniform: IBR is chosen by 20 % of the patients in Stockholm compared to 6 % in the rest of Sweden, indicating differences in information and/or demand [91].

There is an ongoing debate about which reconstructive method is most suitable economically, aesthetically and oncologically. One of the factors in this debate is the increasing use of post-mastectomy radiotherapy [29, 32, 117-123, 129, 130].

The tradition at Karolinska University Hospital has been that, in the absence of contraindications, women in need of a mastectomy are offered an IBR [28, 131]. Advanced surgery with flap technique has not been recommended as a primary procedure for breast cancer. One in three IBR reconstructions has been accompanied by radiotherapy even though this impairs the reconstruction as a result of more capsular contraction and inferior aesthetic results. Compared with mastectomy alone, however, even a poor result with IBR with implants can be a better starting-point for a second procedure.

It is not clear that IBR with implant is invariably the best alternative for women seeking breast reconstruction. Some studies have shown that in the long run, implant-based reconstructions are less aesthetically satisfactory than autologous tissue, but all do not agree on this issue [71, 124, 131, 132].
Still, since implant-based reconstruction probably will be frequently used in the future it is important to continue the development of new implants and to evaluate these in all important aspects. There is no universal solution; one implant does not suit every patient. Moreover, women considering IBR with autologous reconstruction should be included in studies until we know more about the oncological safety of these procedures. Preoperative mapping can be used to predict the risk of adjuvant treatment [124, 125].

Today, breast surgery and reconstructive surgery provide a variety of options, which makes it more difficult but important to tailor surgery, as well as the oncological treatment, to the individual patient (donor site, preferences, expectations, mental health). As each woman is unique, we need to be familiar with all the available reconstructive methods and be properly informed about our patients’ mental and social situation. When the diagnosis of breast cancer is presented to them, patients may be disinclined to accept a reconstructive procedure because this aspect may not be their first concern. Patients should have one separate consultation for information about the advantages and disadvantages of the various forms of reconstruction and have time to consider them before the decision is made at a second visit.

For two years now, the four hospitals in Stockholm at which breast and reconstructive breast surgery are performed (Södersjukhuset, S:t Göran, Danderyd and Karolinska) have regular meetings to discuss issues connected with reconstructive surgery, for example, registration of results and complications, possible future studies, education and accreditation of reconstructive/oncoplastic breast surgeons.

Further education in this field is highly important for breast and plastic surgeons to enable us to meet patients’ wishes with the best individual recommendations.

Further studies of reconstructive breast surgery are needed with PRO questionnaires, methods for objective measurements and aspects on oncological safety. Prospective randomised studies are admittedly difficult but not impossible to perform.
Titel: Primär rekonstruktion med implantat vid bröstcancer- en studie av onkologisk säkerhet och estetiskt resultat.

Behandlingen av bröstcancer har genomgått stora förändringar de senaste decennierna från att initialt avlägsna hela bröstet (mastektomi) till bröstbevarande kirurgi. Förbättrad kunskap om bröstcancerns tumörbiologi har bidragit till utveckling av potenta kemo- och antihormonella behandlingsstrategier i kombination med strålbehandling.

Trots införandet av bröstbevarande kirurgi, som utförs i c:a 50-60 %, rekommenderas årligen mastektomi hos ca 3000 kvinnor i Sverige. Kvinnor som genomgår mastektomi löper större risk att få nedsatt självkänsla, sömnsvårigheter, ökat ångest, depression samt sexuella problem. I enlighet med det nationella vårdprogrammet bör alla kvinnor som rekommenderas mastektomi erbjudas rekonstruktion av bröstet om inget medicinskt hinder föreligger. De psykosociala vinsterna samt de kosmetiska fördelarna med en bröstrekonstruktion är väl dokumenterade.

Syftet med studie I var att studera om primär rekonstruktion med implantat kunde påverka återfallsfrekvens och överlevnad samt att undersöka om tiden till onkologisk tilläggsbehandling fördrojdes. I en retrospektiv långtidsuppföljning (median 11,5 år) jämfördes 300 patienter med invasiv bröstcancer opererade med mastektomi och samtidig rekonstruktion med implantat med 300 matchade patienter opererade med enbart mastektomi. Det förelåg inga signifikanta skillnader mellan grupperna beträffande antalet lokala och regionala återfall samt tid till behandling. Färre fjärrmetastaser samt bättre överlevnad förelåg i den rekonstruerade gruppen vilket kan bero på en selektion av patienter i den rekonstruerade gruppen.


Studie III var ett metodarbete som validerade olika mätmetoder för bröstvolym och form hos sex patienter som skulle genomgå en rekonstruktion samt hos sex patienter som genomgått en rekonstruktion. Resultaten visade stor variation mellan de olika mätmetoderna, där magnetröntgen och 3-dimensionell teknik visade högre volymer jämfört med äldre enklare metoder som vanliga skålar i plast och formbar plast vilken gav den mest exakta volymskattningen. Konturskillnader mellan brösten mättes och kvantifierades med två-dimensionell teknik baserat från 3-D bilder.

Livskvalitet utvärderades med hjälp av SF-36 som är ett validerat frågeformulär där de studerade patienterna jämfördes med en åldersrelaterad normalbefolkning. Resultaten visade att de rekonstruerade patienterna återhämtade sig 1,5 år efter operationen och inga större skillnader kunde ses mellan de två grupperna.

REFERENCES


45. Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M, Kau SW et al. Disease-free and overall survival after pathologic complete disease remission of cytolically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer, 20061; 106:1000-1006.


68. Arion HG. “Retromammary prosthesis”. C R Soc Fr Gynecol 1965; 5.


91. www.karolinska.se/oc, national annual report.


ACKNOWLEDGEMENTS

I wish to express my sincere gratitude to all patients, colleagues and friends. Without you this book would not have been possible. Especially, I would express appreciation to:

Birgit Stark, my main supervisor and dear friend, for your never-ending enthusiasm. I will never forget our early days back at Huddinge Hospital when you got me so inspired that every weekend I waited for Monday morning and a new day at work. I would also like to thank you for sharing your fantastic skills in the operating theatre with me.

Jan Frisell, my supervisor, dear friend and role model. For being the best chief and leader I could ever hope for, always optimistic and always supportive. I would also like to thank you for sharing your scientific knowledge and believing in me.

Kerstin Sandelin, my co-supervisor, for sharing the same ideas and your genuine interest in breast cancer patients and for being a pioneer in the field of primary breast reconstruction.

Göran Jurell, my former co-supervisor who has unfortunately passed away. Thank you for valuable support in the beginning of my research.

Leif Perbeck, the kindest person and colleague I know. For being a clinical mentor and sharing your excellent surgical skills and jokes with me.

Jan Zedenius, my mentor for support and encouragement and for introducing the “filofax” to me.

Marie Wickman, my co-author for clinical and research support. Martin Bäckdahl, Johan Westerdahl, Staffan Gröndal and other former heads of the Departments of Surgery, Breast and Endocrine Surgery and Reconstructive Plastic Surgery for supporting my clinical work and research project.

All my colleagues at the Department of Oncology, for excellent cooperation; I would especially like to thank Elisabet Lidbrink, also my co-author, for support.

All my colleagues at the Department of Reconstructive Plastic Surgery, especially Inkeri Schultz, Jakob Lagergren, Jessica Gahm, Petra Peterson, Filip Farnebo and Martin Halle for being the expert panel in paper IV.

The three musketeers; Hanna Fredholm, Cia Ihrle-Lundgren and Irma Fredriksson, one for all, all for one! Do I have to say more; thank you all for many years of friendship and good work.

Emelie Nordstrand Lindgren, my co-author, and her helpful colleagues at the Department of Medical Imaging for patience and invaluable assistance with all images and 3-D measurements.
Kamilla Krawiec, my co-author, Elisabeth Berg and Hemming Johansson for your support and statistical analyses.

Catarina Bitcover, my college and friend, for your always positive support and your wonderful drawings, including the cover illustration.

Amelia Chiorescu, Jana de Boniface, Helena Sackey, Fredrik Lohmander and Karin Isaksson, my wonderful, lovely room-mates, always contributing with positive comments and help in every way.

Fuat Celebioglu, Lotta Anveden and Peter Emanuelsson, for your friendship and support.

All nurses at Bröstcentrum, Agneta Eriksson, Cecilia Arevald, Elisabeth Göransson, Marianne Unevik, Viveca Åberg and Karolina Fridblom, always so calm, professional and helpful.

All nurses at A23a, especially thanks to Jenny Larsson, Ann Eliasson, Marie Hamnstedt, Karolina Fridblom and Cassie Merenick for helping me with paper I.

All secretaries, especially Carina Ekberg, Chatrin Lindahl, Christel Nilsson and Birgitta Brännström, for keeping order in my world.

My present colleagues at the Department of Breast and Endocrine Surgery and former colleagues at the “Helicopter” for encouragement.

Patrick Hort for patience and invaluable linguistic revisions.

Henrik Olivecrona, my co-author and Stefan Jonson for helping me into the world of 3-D imaging.

To all my other dear friends, colleagues and family for support and help in different ways and for understanding my absence in the past year. But beware! My golf handicap is going to improve.

My family, Mum and Dad, my sister Evelyn and aunt Birgitt, for always being there for me.

My children, Max and Ariel, for truly helping me with my thesis in so many ways and for making me a very proud mother. To Urban, the love of my life, 25 years together, you are rock steady.

This thesis was supported by grants from BRO (Swedish Breast Cancer Association), Olle Engkvist Foundation, Percy Falk Foundation Swedish Cancer Society and ALF.